Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

Open access

Abstract

BACKGROUND: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). METHODS: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overall survival (OS) was a secondary endpoint. RESULTS: Recurrence-free survival was 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR], 0.84; 95% confidence interval [95% CI], 0.62; 1.15). In a planned analysis of RFS rates at yearly intervals, group B showed better outcomes 3 years after transplantation (HR, 0.7; 95% CI, 0.48-1.00). Similarly, OS (P = 0.21; HR, 0.81; 95% CI, 0.58-1.13) was not statistically better in group B at study end, but yearly analyses showed improvement out to 5 years (HR, 0.7; 95% CI, 0.49-1.00). Interestingly, subgroup (Milan Criteria-based) analyses revealed that low-risk, rather than high-risk, patients benefited most from sirolimus; furthermore, younger recipients (age ≤60) also benefited, as well sirolimus monotherapy patients. Serious adverse event numbers were alike in groups A (860) and B (874). CONCLUSIONS: Sirolimus in LTx recipients with HCC does not improve long-term RFS beyond 5 years. However, a RFS and OS benefit is evident in the first 3 to 5 years, especially in low-risk patients. This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/tp.0000000000000965

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Patient disposition. * Reported for one patient who did not withdraw prematurely. ** Patients excluded from the ITT analysis due to violations of major eligibility criteria, as predefined in the statistical analysis plan.
FIGURE 1 Patient disposition. * Reported for one patient who did not withdraw prematurely. ** Patients excluded from the ITT analysis due to violations of major eligibility criteria, as predefined in the statistical analysis plan.CC BY-NC-ND · PubMed Central
FIGURE 2 Efficacy data on ITT population.
FIGURE 2 Efficacy data on ITT population.CC BY-NC-ND · PubMed Central
FIGURE 3 Efficacy data on low-versus high risk subgroups (ITT population).
FIGURE 3 Efficacy data on low-versus high risk subgroups (ITT population).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 456

Metadata

Authors
Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., Wolf, P., Rostaing, L., Bechstein, W. O., Rizell, M., Powell, J., Hidalgo, E., Gugenheim, J., Wolters, H., Brockmann, J., Roy, A., Mutzbauer, I., Schlitt, A., Beckebaum, S., Graeb, C., Nadalin, S., Valente, U., Turrión, V. S., Jamieson, N., Scholz, T., Colledan, M., Fändrich, F., Becker, T., Söderdahl, G., Chazouillères, O., Mäkisalo, H., Pageaux, G.-P., Steininger, R., Soliman, T., de Jong, K. P., Pirenne, J., Margreiter, R., Pratschke, J., Pinna, A. D., Hauss, J., Schreiber, S., Strasser, S., Klempnauer, J., Troisi, R. I., Bhoori, S., Lerut, J., Bilbao, I., Klein, C. G., Königsrainer, A., Mirza, D. F., Otto, G., Mazzaferro, V., Neuhaus, P., & Schlitt, H. J.
Affiliations
  • University of Padua (IT)
  • University Hospital Regensburg (DE)
  • Université Paris-Est Créteil (FR)
  • LMU Klinikum (DE)
  • University Hospital Heidelberg (DE)
  • Jena University Hospital (DE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
  • University Hospital Frankfurt (DE)
Corresponding author
Geissler, Edward K.
Venue
Transplantation
Published
2016-01
Volume
100
Issue
1
Pages
116-125
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2173253647
Cited by
433
References
39
Citations by year
2026: 27 · 2025: 24 · 2024: 53 · 2023: 36 · 2022: 43 · 2021: 54 · 2020: 46 · 2019: 37 · 2018: 38 · 2017: 44 · 2016: 26
FWCI
21.89
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Transplantation (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Digital Access to Libraries (submittedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Pfizer
  • Universitätsklinikum Regensburg
  • Universität Regensburg
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
rapamycin, liver transplantation, hepatocellular carcinoma, mTOR inhibitors, immunosuppression, recurrence-free survival, overall survival, Milan criteria, patient selection, adverse events
MeSH terms
Adult, Age Factors, Aged, Australia, Canada, Drug Therapy, Combination, Europe, Female, Carcinoma, Hepatocellular, Humans, Immunosuppressive Agents, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Risk Factors, Time Factors, Liver Transplantation, Treatment Outcome, Disease Progression, Risk Assessment, Disease-Free Survival, Sirolimus, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. https://app.cochat.ai/papers/10.1097/tp.0000000000000965
The paper
Geissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., Schmidt, J., Settmacher, U., Heise, M., Rossi, G., Cillo, U., Kneteman, N., Adam, R., van Hoek, B., Bachellier, P., . . . Schlitt, H. J. (2016). Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. https://doi.org/10.1097/tp.0000000000000965

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.